ISB News

ISB Featured in Google I/O Conference Keynote

We were very excited to watch the live stream of the keynote from the Google I/O conference today, because it featured work from ISB's Shmulevich Lab, which is one of a group of research organizations that has been working on The Cancer Genome Atlas (TCGA). To help visualize the TCGA data, the lab created the Cancer Regulome Explorer using Google App Engine and Google Compute Engine. Google Compute Engine is just part of what Google sees as a whole new way for scientists around the world to work more effectively in the cloud, not only by accessing powerful computational resources, but by collaborating more easily on complex research.

Funding for ISB's research comes from TCGA and the National Cancer Institute.

[Update 2:04 p.m.]

Here's a link to the "Behind the Compute Engine demo at Google I/) 2012 Keynote." It explains how the technology is being used at ISB.

[Update 3:39 p.m.]

ISB's Ilya Shmulevich and Hector Rovira were quoted in this white paper on ISB's use of Google Compute Engine.

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.